Literature DB >> 6250759

Dose response in captopril therapy of hypertension.

P Lijnen, R Fagard, J Staessen, L J Verschueren, A Amery.   

Abstract

Dose-response curves of blood pressure and of the biochemical components of the renin-angiotensin-aldosterone system were determined during long-term treatment with captopril in 21 hypertensive patients. Captopril was given in biweekly, doubling doses starting with 25 mg 3 times a day until control of blood pressure was achieved or a total daily dosage of 600 mg was reached. Recumbent and standing systolic and diastolic blood pressure fell on 75 mg captopril daily. Increasing the captopril dose did not induce further significant hypotensive effects. The pretreatment level of plasma renin activity (PRA) was a poor predictor of the hypotensive effect of captopril. The rises in PRA and plasma angiotensin I level (PA I) and the decrease in plasma angiotensin II level (PA II) and plasma aldosterone level (PAC) provide biochemical evidence for angiotensin-converting enzyme (ACE) inhibition in vivo. These effects were present on daily doses of 75 to 150 mg captopril.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6250759     DOI: 10.1038/clpt.1980.167

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

Review 1.  Selecting appropriate antihypertensive drug dosages.

Authors:  G D Johnston
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

2.  Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease.

Authors:  Matthew L Hemming; Dennis J Selkoe; Wesley Farris
Journal:  Neurobiol Dis       Date:  2007-01-25       Impact factor: 5.996

Review 3.  Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.